Lynne Lederman, PhD


Luspatercept Reduces Transfusion Burden in Transfusion-Dependent Patients With Beta-Thalassemia

December 11th 2019

A majority of adult patients with β-thalassemia who require regular red blood cell transfusions experienced clinically meaningful and durable transfusion burden reduction associated with luspatercept (Reblozyl).

Initial Higher-Dose Duvelisib Improves Responses in Relapsed/Refractory PTCL

December 9th 2019

Patients with relapsed/refractory peripheral T-cell lymphoma who received a higher initial dose of duvelisib at 75 mg BID had a higher overall response rate of 62% than those who received 25 mg BID.

Selinexor Triplet Highly Active in Relapsed Myeloma

September 16th 2019

The all-oral triplet regimen of 60 mg of weekly selinexor plus lenalidomide and dexamethasone appears to be highly active and well-tolerated in patients with relapsed, refractory multiple myeloma, particularly in patients who did not receive prior lenalidomide, according to results of the multi-arm STOMP study that were presented during the 17th International Myeloma Workshop.

Anti-BCMA BiTE AMG 701 Shows Preclinical Promise in Multiple Myeloma

September 16th 2019

AMG 701, a half-life–extended anti-BCMA bispecific T-cell engager, showed promising in vitro antimyeloma activity and characteristics suitable for once-weekly dosing in patients with multiple myeloma, according to findings presented at the 17th International Myeloma Workshop.

Melflufen Regimen Elicits Activity in Relapsed Myeloma With Extramedullary Disease

September 16th 2019

Melflufen and dexamethasone demonstrated encouraging activity in patients with relapsed/refractory multiple myeloma with and without extramedullary disease, with response rates higher than those observed in prior studies of other agents.

Daratumumab Plus VRd Shows Improved sCR in Transplant-Eligible, Newly Diagnosed Myeloma

September 15th 2019

The addition of daratumumab to bortezomib, lenalidomide, and dexamethasone for transplant-eligible patients with newly diagnosed multiple myeloma improved the depth of response without affecting stem cell mobilization or hematopoietic reconstitution.

Iberdomide Shows Promise in Heavily Pretreated Multiple Myeloma

September 15th 2019

The novel agent iberdomide (formerly CC-220) was safe and showed antitumor activity when combined with dexamethasone in patients with heavily pretreated, relapsed/refractory multiple myeloma, according to findings from a phase Ib/IIa study presented at the 17th International Myeloma Workshop.

Isatuximab Quadruplet Active in High-Risk, Newly Diagnosed Myeloma

September 14th 2019

A quadruplet regimen combining the anti-CD38 monoclonal antibody isatuximab with carfilzomib, lenalidomide, and dexamethasone was safe and had a 100% response rate among 10 patients enrolled in the safety run-in cohort of the phase II, multicenter GMMG-CONCEPT trial.

Findings Clarify Picture for HER2-Positive Breast Cancer

May 1st 2018

A panel of experts discuss the latest developments in the treatment of patients with HER2-positive breast cancer.

Encouraging Activity Seen With Glembatumumab Vedotin in Advanced Melanoma

July 14th 2017

The antibody-drug conjugate glembatumumab vedotin demonstrated an 11% overall response rate in patients with refractory advanced melanoma who had received prior treatment with a checkpoint inhibitor and duration of response.